Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : CDC finds reactions to booster dose of COVID-19 vaccine similar to second

09/28/2021 | 02:03pm EDT

Side effects reported among recipients of a COVID-19 booster vaccine are similar to those seen after the second dose, the Centers for Disease Control and Prevention reported Tuesday.

The findings are based on reports made from roughly 12,600 booster-dose recipients to the CDC's voluntary vaccine safety surveillance program, which tracks shot side effects.

While booster shots are still being studied for most groups of people, the FDA in August authorized booster doses of the Pfizer-BioNTech and Moderna vaccines for solid transplant recipients and people with compromised immune systems.

The Food and Drug Administration last week recommended third, booster doses of the Pfizer-BioNTech vaccine for adults age 65 and older and those with chronic health conditions, such as diabetes and heart disease, that place them at increased risk for severe COVID-19.

However, the agency has not yet recommended additional doses for the Moderna or Johnson & Johnson vaccines, though the manufacturers of both have been conducting clinical trials of boosters to determine their safety, as well as if they are needed.

"During the period covered by this study, recommendations for an additional dose of COVID-19 vaccine were limited to persons with moderately to severely immunocompromising conditions who had received two doses of an mRNA vaccine," the agency researchers wrote.

Of the 12,600 booster recipients included in the report, 79% indicated they experienced injection-site reactions, including pain and swelling, the data showed.

In addition, 74% said they had fatigue, muscle pain or headaches, among other "systemic" reactions, following receipt of the third dose, the agency said.

These figures are similar to those reported following the second dose of the vaccines, when just under 78% indicated they had injection-site reactions and about 77% experienced systemic side effects.

"No unexpected patterns of adverse reactions were identified," the CDC researchers wrote.

"Those reported were mild to moderate and transient," meaning they resolved on their own, they said.

More than 22,000 people reported receiving a booster dose of a COVID-19 vaccine -- either the two-dose shots from Moderna and Pfizer-BioNTech or the one-dose Johnson & Johnson vaccine -- between Aug. 12 and Sept. 19, the agency said.

However, not all of them submitted information on side effects they experienced following receipt of the booster, according to the CDC.

The vast majority of booster dose recipients were given either the Moderna or Pfizer-BioNTech vaccines, with fewer than 200 people opting for an additional Johnson & Johnson shot.

Reports of side effects following the additional dose were similar for all three, the CDC reported.

Pain and swelling were the most common injection-site reactions reported for both the Moderna and Pfizer-BioNTech booster doses, though itchiness and redness were more common with the Moderna shot than the similarly formulated Pfizer-BioNTech product.

Among systemic reactions to the shots, fatigue, headache and muscle pain were the most common with the Pfizer-BioNTech vaccine, though joint pain, fever, chills and nausea were each reported by at least 10% of recipients.

For the Moderna shot, fatigue, muscle pain and headache were the most common side effects reported with the third dose, while fever, chills and joint pain occurred in at least 30% of recipients.

Copyright 2021 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source Health News - Business

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON 0.20% 163.72 Delayed Quote.4.03%
MODERNA, INC. -3.84% 326.54 Delayed Quote.212.57%
All news about MODERNA, INC.
04:01pMODERNA : U.S. has administered nearly 414 mln doses of COVID-19 vaccines
RE
03:32pMODERNA : U.S. has administered nearly 414 mln doses of COVID-19 vaccines
RE
03:14pMODERNA : U.S. CDC Says Administered 413,645,478 Doses Of Covid-19 Vaccine As Of Oct 24
RE
12:04aAP NEWS IN BRIEF AT 6 : 04 p.m. EDT
AQ
10/23MODERNA : U.S. CDC Says Delivered 503,521,625 Doses Of Covid-19 Vaccine As Of Oct 23
RE
10/22MODERNA : Canada considers what to do with millions of unused COVID-19 vaccine doses
AQ
10/22MODERNA : U.S. administers nearly 412 mln doses of COVID-19 vaccines - CDC
RE
10/22MODERNA : COVID SCIENCE-COVID-19 vaccines not linked to pregnancy loss; mixing vaccines ma..
RE
10/22CVS HEALTH : Pharmacies Start Offering Moderna COVID-19 Booster Shots
MT
10/22EXPLAINER : Is it time to get a COVID-19 booster? Which one?
AQ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 20 374 M - -
Net income 2021 12 558 M - -
Net cash 2021 13 559 M - -
P/E ratio 2021 10,9x
Yield 2021 -
Capitalization 132 B 132 B -
EV / Sales 2021 5,80x
EV / Sales 2022 5,10x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Last Close Price 326,54 $
Average target price 295,79 $
Spread / Average Target -9,42%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 076
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455
ALNYLAM PHARMACEUTICALS, INC.52.81%23 604